Crispr Therapeutics vs Precigen
Precigen is the larger business, with $9.7m of revenue in fiscal 2025 against $3.5m for Crispr Therapeutics (2.8 times as much). Precigen grew faster (146.7% against -90.6%). Precigen kept more of each dollar of sales as profit: a net margin of -2588.2% against -16569.8%. Crispr Therapeutics carries less debt relative to equity (0.0% against 478.2%).
| Latest fiscal year | Crispr TherapeuticsCRSP, 2025 | PrecigenPGEN, 2025 |
|---|---|---|
| Revenue | $3.5m | $9.7m |
| Revenue growth | -90.6% | 146.7% |
| Net income | −$582m | −$251m |
| Operating margin | -18933.6% | -1141.1% |
| Net margin | -16569.8% | -2588.2% |
| Return on equity | -30.2% | — |
| Free cash flow | −$346m | −$89.8m |
| Cash | $348m | $30.2m |
| Total debt | $0 | $100m |
| Debt to equity | 0.0% | 478.2% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $4.83bn | $1.84bn |
| Price vs our value range | — | — |
| Moat score | 10 (Weak) | 9 (Weak) |
| Insider trades, 12 months | 0 buys, 30 sales | 1 buys, 40 sales |